Passage Bio, Inc. PASG

Company Overview

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic central nervous system (CNS) disorders. The company operates within the biotechnology and gene therapy industries, with research and development centered on inherited neurodegenerative and neurodevelopmental diseases that currently have limited or no approved disease-modifying treatments. Its primary value drivers are its clinical and preclinical gene therapy programs, intellectual property related to CNS-targeted AAV delivery, and collaborations with leading academic research institutions.

The company was founded in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio was established through a strategic partnership with the University of Pennsylvania’s Gene Therapy Program, leveraging research developed by pioneers in AAV-based genetic medicine. The company completed its initial public offering in 2020 and has since focused on advancing therapies for diseases such as frontotemporal dementia (FTD) associated with progranulin deficiency and other rare neurological conditions. Its positioning is supported by access to translational research expertise, established manufacturing relationships, and a focus on orphan CNS indications where regulatory incentives and high unmet need may support development opportunities.

Business Operations

Passage Bio’s operations are primarily organized around its research and development pipeline rather than diversified commercial segments, as the company remains in the clinical development stage and does not currently generate product revenue. Revenue historically has consisted primarily of collaboration-related activities, interest income, and financing transactions. The company’s core business activities include discovery research, clinical development, regulatory engagement, and manufacturing coordination for AAV gene therapies targeting CNS disorders. Its lead clinical candidate has been PBFT02, a progranulin gene replacement therapy for frontotemporal dementia with GRN mutations.

The company conducts operations primarily in the United States, while utilizing external contract development and manufacturing organizations for vector production and clinical supply. Passage Bio maintains strategic ties with the University of Pennsylvania and affiliated researchers for scientific collaboration and technology access. The company controls a portfolio of licensed intellectual property covering gene therapy constructs, delivery approaches, and CNS-focused AAV applications. Public disclosures also indicate reliance on specialized third-party manufacturers and clinical research organizations to support trial execution and regulatory activities.

Strategic Position & Investments

Passage Bio’s strategic direction has focused on advancing targeted CNS gene therapies through disciplined capital allocation and prioritization of high-potential rare disease programs. The company has emphasized clinical development in genetically defined neurological disorders where biomarker-driven endpoints and orphan drug pathways may provide regulatory advantages. In recent years, management has undertaken portfolio prioritization efforts to extend cash runway and concentrate resources on programs considered most likely to generate meaningful clinical data.

The company’s major strategic assets include its exclusive licensing arrangements with the University of Pennsylvania and associated access to gene therapy research infrastructure. Passage Bio has invested in AAV vector development, translational neuroscience capabilities, and clinical-stage manufacturing partnerships rather than large-scale acquisitions. Its activities place it within broader emerging sectors such as genomic medicine, precision neurology, and next-generation CNS therapeutics. Public filings and investor materials also indicate ongoing evaluation of business development opportunities and pipeline optimization initiatives as part of its long-term strategy.

Geographic Footprint

Passage Bio is headquartered in Philadelphia, Pennsylvania, and its operational footprint is concentrated primarily in the United States. Clinical development activities have included collaborations with medical institutions, research centers, and clinical trial sites across North America. The company’s scientific ecosystem is closely connected to the biotechnology and academic research network surrounding the University of Pennsylvania.

Although Passage Bio does not maintain the extensive commercial infrastructure of larger multinational pharmaceutical companies, its programs have relevance to global rare disease markets, particularly in North America and Europe, where orphan drug frameworks support development of advanced therapies. The company also relies on international manufacturing and supply-chain relationships common within the gene therapy industry, including specialized production and testing vendors that support global clinical development standards.

Leadership & Governance

Passage Bio’s leadership team consists of biotechnology executives and scientific leaders with backgrounds in gene therapy, neuroscience, clinical development, and biopharmaceutical operations. Governance and strategic oversight are provided through a board and executive structure focused on advancing rare disease therapeutics while managing the financial and regulatory demands associated with clinical-stage biotechnology companies.

Key executives identified in public company disclosures include:

• Will Chou, M.D. – President and Chief Executive Officer
• Khurem Farooq – Former Chief Executive Officer and Board member
• Howard J. Weiner, M.D. – Chief Medical Advisor roles associated with clinical strategy in prior company disclosures
• Anupam “AP” Patel – Chief Financial Officer in prior public filings and corporate updates
• Richard Morris, Ph.D. – Scientific leadership roles connected to translational and research operations in historical disclosures

The company’s leadership philosophy, as reflected in investor communications and regulatory filings including SEC filings and annual reports, emphasizes rigorous clinical execution, scientific collaboration, and focused development of transformative therapies for severe neurological diseases with high unmet medical need. Public information indicates management has also prioritized operational efficiency and strategic portfolio refinement in response to broader biotechnology market conditions.